Sanofi stock­pil­ing medicines in UK to cope with pos­si­ble Brexit no-deal

Irish Independent - Business Week - - Front Page - Matthias Bla­m­ont

SANOFI yes­ter­day said it had made ar­range­ments for ad­di­tional ware­house ca­pac­ity in Bri­tain to stock­pile drugs, as it makes con­tin­gency plans for a po­ten­tial no-deal over Brexit ne­go­ti­a­tions.

Sanofi said it was con­fi­dent its stock­pil­ing mea­sures would en­sure Bri­tish pa­tients have ac­cess to its treat­ments af­ter Bri­tain leaves the EU, re­gard­less of whether a deal over its fu­ture re­la­tions with the bloc is in place.

The move high­lights grow­ing con­cern among ma­jor Euro­pean com­pa­nies from re­tail to phar­ma­ceu­ti­cals over the dis­rup­tion that Bri­tain crash­ing out of the EU in March next year would cause to sup­ply chains.

“The un­cer­tainty in the Brexit ne­go­ti­a­tions means that Sanofi has al­ways been plan­ning for a no-deal sce­nario,” a spokesman with the French drug­maker said.

“We have made ar­range­ments for ad­di­tional ware­house ca­pac­ity in or­der to stock­pile our prod­ucts in the UK and in­crease UK-based re­sources to pre­pare for any changes to cus­toms or reg­u­la­tory pro­cesses.”

The Euro­pean Medicines Agency has warned drug­mak­ers they needed to be ready for a pos­si­ble hard Brexit in 2019.

It has also ex­pressed “se­ri­ous con­cerns” over the avail­abil­ity of some 108 medicines that are man­u­fac­tured ex­clu­sively in the UK.

More than 2,600 drugs have some stage of man­u­fac­ture in Bri­tain and 45 mil­lion patient packs are sup­plied from the United King­dom to other Euro­pean coun­tries each month, while another 37 mil­lion flow in the op­po­site di­rec­tion, in­dus­try fig­ures show.

Ear­lier this month, Bri­tish drug­maker As­traZeneca said it was in­creas­ing stock­piles of those medicines in Bri­tain and con­ti­nen­tal Europe that could be af­fected by Brexit by around 20pc.

The ‘Wall Street Jour­nal’, which first re­ported the stock­pil­ing by Sanofi late on Tues­day, said the drug­maker was in­creas­ing stocks for all ther­a­pies by four weeks to a to­tal of 14 weeks. (Reuters)

Newspapers in English

Newspapers from Ireland

© PressReader. All rights reserved.